Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes
复制标题
DOI：
10.1152/ajpregu.00287.2005
复制
发表时间：
2006-01-01
影响因子：
2.8
通讯作者：
Reaven, PD
中科院分区：
文献类型：
--
作者：
Abbasi, F;Chang, SA;Reaven, PD
已有研究表明，脂联素水平的变化可能有助于胰岛素抵抗个体在减肥后和使用噻唑烷二酮类化合物治疗后胰岛素敏感性的改善。如果这是正确的，那么总循环脂联素和/或其多聚体复合体分布的变化应该与两种干预措施后胰岛素敏感性的改善相一致。为了解决这个问题，我们检测了24名胰岛素抵抗的非糖尿病受试者在罗格列酮或热量限制治疗3-4个月前后的空腹脂联素浓度和血浆中脂联素复合体的分布。每组12名受试者的胰岛素抵抗程度在基线时相同，在每次治疗后改善程度相似(接近30%)。罗格列酮治疗组总脂联素水平增加近3倍，几种较高分子量脂联素复合体的相对数量显著增加，而减肥组的脂联素水平或高、低分子复合体之间的分布没有明显变化。这些数据表明，尽管在接受噻唑烷二酮治疗的受试者中，总脂联素和几种特定的脂联素复合体的变化与胰岛素抵抗的改善是平行的，但在12名胰岛素抵抗的肥胖者中，在适度减肥后，循环中的脂联素浓度和多聚体复合体都没有与胰岛素敏感性的增强相关。
It has been suggested that changes in adiponectin levels may contribute to improved insulin sensitivity in insulin-resistant individuals both after weight loss and after treatment with thiazolidinedione compounds. If this is correct, then changes in total circulating adiponectin and/or distribution of its multimeric complexes should coincide with improvements in insulin sensitivity after both interventions. To address this issue, fasting adiponectin concentrations and distribution of adiponectin complexes were measured in plasma samples in 24 insulin-resistant, nondiabetic subjects before and after 3-4 mo of treatment with either rosiglitazone or caloric restriction. The degree of insulin resistance in each group of 12 subjects was equal at baseline and improved to a similar extent (similar to 30%) after each therapy. Whereas total adiponectin levels increased by nearly threefold and the relative amount of several higher molecular weight adiponectin complexes increased significantly in the rosiglitazone treatment group, there were no discernible changes in adiponectin levels or in the distribution between high or low molecular weight complexes in the weight loss group. These data indicate that, although changes in total adiponectin and several specific adiponectin complexes paralleled improvements in insulin resistance in thiazolidinedione- treated subjects, neither circulating adiponectin concentrations nor multimeric complexes changed in association with enhanced insulin sensitivity after moderate weight loss in 12 insulin-resistant, obese individuals.